ES2492681T3 - Método cromatográfico para purificar proteínas que contienen FC - Google Patents
Método cromatográfico para purificar proteínas que contienen FC Download PDFInfo
- Publication number
- ES2492681T3 ES2492681T3 ES11700457.2T ES11700457T ES2492681T3 ES 2492681 T3 ES2492681 T3 ES 2492681T3 ES 11700457 T ES11700457 T ES 11700457T ES 2492681 T3 ES2492681 T3 ES 2492681T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- concentration
- sought
- mobile phase
- stationary phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Abstract
Método para disminuir las impurezas de una composición que contiene una proteína con el dominio Fc de una inmunoglobulina (proteína buscada) mediante una cromatografía de proteína A que consta de las siguientes etapas: a) uso de una fase móvil que contiene la proteína buscada sobre una fase estacionaria que lleva la proteína A, en unas condiciones en que la proteína buscada se fija a la fase estacionaria; b) uso de un tampón de lavado con un pH comprendido entre 5 y 8 como fase móvil, que lleva como aditivos i) arginina a una concentración de 0,1 - 1 mol/l, ii) cloruro sódico a una concentración de 0,2 hasta 2 mol/l, iii) un alcohol elegido del grupo formado por isopropanol, n-propanol y etanol a una concentración del 5 - 30% (p/v) y iv) polivinilpirrolidona o un detergente a una concentración del 0,05 - 2% (p/v); c) uso de un tampón de elución como fase móvil, en unas condiciones en que la proteína buscada es eluida de la fase estacionaria.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10151416 | 2010-01-22 | ||
| EP10151416 | 2010-01-22 | ||
| EP10171975 | 2010-08-05 | ||
| EP10171975 | 2010-08-05 | ||
| PCT/EP2011/050817 WO2011089212A1 (de) | 2010-01-22 | 2011-01-21 | Chromatographisches verfahren zur aufreinigung von fc enthaltenden proteinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2492681T3 true ES2492681T3 (es) | 2014-09-10 |
Family
ID=43598239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11700457.2T Active ES2492681T3 (es) | 2010-01-22 | 2011-01-21 | Método cromatográfico para purificar proteínas que contienen FC |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9284347B2 (es) |
| EP (1) | EP2526114B1 (es) |
| JP (1) | JP5567691B2 (es) |
| KR (1) | KR101753569B1 (es) |
| CN (1) | CN102712673B (es) |
| AU (1) | AU2011208659B2 (es) |
| CA (1) | CA2784959C (es) |
| DK (1) | DK2526114T3 (es) |
| ES (1) | ES2492681T3 (es) |
| SG (1) | SG182553A1 (es) |
| WO (1) | WO2011089212A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560738B8 (en) * | 2010-04-23 | 2019-09-25 | Serum Institute of India Private Limited | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
| EP2714714B1 (en) * | 2011-06-01 | 2018-06-20 | Novartis AG | Wash solution and method for affinity chromatography |
| EP2992021B1 (en) | 2013-04-30 | 2020-07-22 | Intas Pharmaceuticals Limited | Novel cloning, expression & purification method for the preparation of ranibizumab |
| TWI596107B (zh) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
| MX2016016318A (es) * | 2014-06-13 | 2017-06-12 | Lupin Atlantis Holdings Sa | Proceso para la purificacion de la proteina de fusion. |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3241849A4 (en) | 2014-12-31 | 2018-06-20 | LG Chem, Ltd. | Method for producing tnfr-fc fusion protein containing target content of impurities |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| KR20200083491A (ko) | 2017-11-14 | 2020-07-08 | 바이오-소싱 에스.에이. | 항체 정제 |
| EP3546475A1 (en) * | 2018-03-27 | 2019-10-02 | Sanofi | Full flow-through process for purifying recombinant proteins |
| WO2020125757A1 (en) * | 2018-12-21 | 2020-06-25 | Wuxi Biologics (Shanghai) Co., Ltd. | A method for improving aggregate removal by protein a chromatography |
| CN111333776B (zh) * | 2020-03-20 | 2021-11-09 | 暨南大学 | 一种氮杂环类有机聚合物整体材料及制备与应用 |
| WO2024017826A2 (en) * | 2022-07-19 | 2024-01-25 | Glaxosmithkline Intellectual Property Development Limited | Methods for purifying recombinant polypeptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874218A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| US5585246A (en) * | 1993-02-17 | 1996-12-17 | Biometric Imaging, Inc. | Method for preparing a sample in a scan capillary for immunofluorescent interrogation |
| CA2473144C (en) | 2002-02-05 | 2013-05-28 | Genentech, Inc. | Protein purification |
| US8084032B2 (en) * | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| US20070172846A1 (en) * | 2005-11-12 | 2007-07-26 | Introgen Therapeutics, Inc. | Methods for the Production and Purification of Adenoviral Vectors |
| WO2007081906A2 (en) | 2006-01-06 | 2007-07-19 | Amgen Inc. | Purification by column-chromatography using eluants containing organic solvents |
| WO2007109163A2 (en) * | 2006-03-16 | 2007-09-27 | Amgen Inc | Wash buffer and method of using |
| CN101511387A (zh) * | 2006-09-08 | 2009-08-19 | 惠氏公司 | 使用亲和色谱法纯化蛋白质的精氨酸洗涤液 |
| WO2010147686A2 (en) * | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| ES2982297T3 (es) * | 2009-12-18 | 2024-10-15 | Novartis Ag | Método de cromatografía de afinidad |
-
2011
- 2011-01-21 SG SG2012052452A patent/SG182553A1/en unknown
- 2011-01-21 US US13/522,030 patent/US9284347B2/en active Active
- 2011-01-21 ES ES11700457.2T patent/ES2492681T3/es active Active
- 2011-01-21 JP JP2012549368A patent/JP5567691B2/ja active Active
- 2011-01-21 CN CN201180006652.0A patent/CN102712673B/zh active Active
- 2011-01-21 WO PCT/EP2011/050817 patent/WO2011089212A1/de not_active Ceased
- 2011-01-21 AU AU2011208659A patent/AU2011208659B2/en active Active
- 2011-01-21 CA CA2784959A patent/CA2784959C/en active Active
- 2011-01-21 KR KR1020127019071A patent/KR101753569B1/ko active Active
- 2011-01-21 DK DK11700457.2T patent/DK2526114T3/da active
- 2011-01-21 EP EP11700457.2A patent/EP2526114B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011208659B2 (en) | 2015-05-28 |
| WO2011089212A1 (de) | 2011-07-28 |
| SG182553A1 (en) | 2012-08-30 |
| HK1174044A1 (en) | 2013-05-31 |
| EP2526114B1 (de) | 2014-06-18 |
| CN102712673A (zh) | 2012-10-03 |
| AU2011208659A1 (en) | 2012-07-19 |
| KR20120118013A (ko) | 2012-10-25 |
| CN102712673B (zh) | 2014-04-30 |
| JP2013517318A (ja) | 2013-05-16 |
| DK2526114T3 (da) | 2014-09-29 |
| KR101753569B1 (ko) | 2017-07-04 |
| EP2526114A1 (de) | 2012-11-28 |
| JP5567691B2 (ja) | 2014-08-06 |
| US9284347B2 (en) | 2016-03-15 |
| CA2784959A1 (en) | 2011-07-28 |
| US20130197197A1 (en) | 2013-08-01 |
| CA2784959C (en) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2492681T3 (es) | Método cromatográfico para purificar proteínas que contienen FC | |
| AR062570A1 (es) | Proceso para la purificacion de las proteinas que contienen fc | |
| ES2500066T3 (es) | Anticuerpos frente a ferroportina y métodos de uso | |
| MX2019000898A (es) | Amortiguador de lavado de cromatografia de afinidad. | |
| ES2524786T3 (es) | Uso de quelantes inmovilizados para purificación de proteínas recombinantes por cromatografía de iones metálicos inmovilizados y método de purificación de proteínas recombinantes | |
| CL2012001966A1 (es) | Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis. | |
| MX395730B (es) | Uso de lavados alcalinos durante la cromatografia para remover impurezas. | |
| RU2012130151A (ru) | Промывочный раствор и способ промывки для аффинной хроматографии | |
| EA201290076A1 (ru) | Специфичный сорбент для связывания белков и пептидов и способ выделения с его использованием | |
| MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
| ES2585580T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
| BRPI0806737A8 (pt) | uso de sistema de renomeação de registrador para encaminhar resultados intermediários entre instruções constituintes de uma instrução expandida | |
| MX2012000615A (es) | Proceso y sistema para obtener neurotoxina botulinica. | |
| EA201592192A1 (ru) | Способ очистки моноклональных антител | |
| PH12013501128A1 (en) | Antibody purification by cation exchange chromatography | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| MX363380B (es) | Formulacion de anticuerpos. | |
| AR085138A1 (es) | VARIANTES DE Fc Y METODOS PARA SU PRODUCCION | |
| AR070633A1 (es) | Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr) | |
| AR097791A1 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| BR112015011749A2 (pt) | controle do uso de um único espaço de estacionamento para múliplos veículos utilizando múltiplas câmeras | |
| AR063840A1 (es) | Anticuerpos humanos monoclonales para btla y metodos de uso | |
| PE20150996A1 (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
| BR112015022119A2 (pt) | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento | |
| MX2019015304A (es) | Amortiguador de lavado para cromatografia de intercambio cationico. |